Literature DB >> 23788007

Amyloid and tau neuropathology differentially affect prefrontal synaptic plasticity and cognitive performance in mouse models of Alzheimer's disease.

Adrian C Lo1, Emilia Iscru, David Blum, Ina Tesseur, Zsuzsanna Callaerts-Vegh, Luc Buée, Bart De Strooper, Detlef Balschun, Rudi D'Hooge.   

Abstract

Alzheimer's disease (AD) is a consequence of degenerative brain pathology with amyloid plaque deposition and neurofibrillary tangle formation. These distinct aspects of AD neuropathology have been suggested to induce a cascade of pathological events ultimately leading to neurodegeneration as well as cognitive and behavioral decline. Amyloid and tau neuropathology is known to develop along distinct stages and affect parts of the brain differentially. In this study, we examined two mouse AD lines (AβPPPS1-21 and Tau22 mice), which mimic different partial aspects of AD pathology, at comparable stages of their pathology. Since prefrontal cortex (PFC) is one of the first regions to be affected in clinical AD, we compared long-term potentiation (LTP) of synaptic responses in medial PFC of AβPPPS1-21 and Tau22 mice. Frontal LTP was impaired in AβPPPS1-21 mice, but not in Tau22 mice. Consequently, we observed different behavioral defects between AβPPPS1-21 and Tau22 animals. Apart from spatial learning deficits, AβPPPS1-21 transgenic mice were impaired in fear learning, aversion learning, and extinction learning, whereas THY-Tau22 were impaired in appetitive responding. Discriminant function analysis identified critical behavioral variables that differentiated AβPPPS1-21 and THY-Tau22 mice from wild type littermates, and further confirmed that amyloid- versus tau-pathology differentially affects brain function.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23788007     DOI: 10.3233/JAD-122296

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  14 in total

Review 1.  Cognitive reserve and Alzheimer's disease.

Authors:  Wei Xu; Jin-Tai Yu; Meng-Shan Tan; Lan Tan
Journal:  Mol Neurobiol       Date:  2014-05-04       Impact factor: 5.590

2.  Metabolic Dysfunction of Astrocyte: An Initiating Factor in Beta-amyloid Pathology?

Authors:  Liang-Jun Yan; Ming Xiao; Ran Chen; Zhiyou Cai
Journal:  Aging Neurodegener       Date:  2013-08

3.  Polymeric alkylpyridinium salts permit intracellular delivery of human Tau in rat hippocampal neurons: requirement of Tau phosphorylation for functional deficits.

Authors:  Dave J Koss; Lianne Robinson; Anna Mietelska-Porowska; Anna Gasiorowska; Kristina Sepčić; Tom Turk; Marcel Jaspars; Grazyna Niewiadomska; Roderick H Scott; Bettina Platt; Gernot Riedel
Journal:  Cell Mol Life Sci       Date:  2015-06-13       Impact factor: 9.261

4.  Regular exercise prevents non-cognitive disturbances in a rat model of Alzheimer's disease.

Authors:  An T Dao; Munder A Zagaar; Samina Salim; Jason L Eriksen; Karim A Alkadhi
Journal:  Int J Neuropsychopharmacol       Date:  2013-11-14       Impact factor: 5.176

Review 5.  From epidemiology to pathophysiology: what about caffeine in Alzheimer's disease?

Authors:  Vanessa Flaten; Cyril Laurent; Joana E Coelho; Ursula Sandau; Vânia L Batalha; Sylvie Burnouf; Malika Hamdane; Sandrine Humez; Detlev Boison; Luísa V Lopes; Luc Buée; David Blum
Journal:  Biochem Soc Trans       Date:  2014-04       Impact factor: 5.407

6.  Human Neural Stem Cell Transplantation Rescues Cognitive Defects in APP/PS1 Model of Alzheimer's Disease by Enhancing Neuronal Connectivity and Metabolic Activity.

Authors:  Xueyuan Li; Hua Zhu; Xicai Sun; Fuxing Zuo; Jianfeng Lei; Zhanjing Wang; Xinjie Bao; Renzhi Wang
Journal:  Front Aging Neurosci       Date:  2016-11-23       Impact factor: 5.750

7.  Amyloid β Peptide-Induced Changes in Prefrontal Cortex Activity and Its Response to Hippocampal Input.

Authors:  Ernesto Flores-Martínez; Fernando Peña-Ortega
Journal:  Int J Pept       Date:  2017-01-03

8.  SAR110894, a potent histamine H3-receptor antagonist, displays disease-modifying activity in a transgenic mouse model of tauopathy.

Authors:  Philippe Delay-Goyet; Véronique Blanchard; Nathalie Schussler; Mati Lopez-Grancha; Jean Ménager; Véronique Mary; Eric Sultan; Armelle Buzy; Jean-Claude Guillemot; Jeanne Stemmelin; Philippe Bertrand; Thomas Rooney; Laurent Pradier; Pascal Barnéoud
Journal:  Alzheimers Dement (N Y)       Date:  2016-11-03

9.  Deregulation of neuronal miRNAs induced by amyloid-β or TAU pathology.

Authors:  Annerieke Sierksma; Ashley Lu; Evgenia Salta; Elke Vanden Eynden; Zsuzsanna Callaerts-Vegh; Rudi D'Hooge; David Blum; Luc Buée; Mark Fiers; Bart De Strooper
Journal:  Mol Neurodegener       Date:  2018-10-12       Impact factor: 14.195

10.  Novel Alzheimer risk genes determine the microglia response to amyloid-β but not to TAU pathology.

Authors:  Annerieke Sierksma; Ashley Lu; Bart De Strooper; Mark Fiers; Renzo Mancuso; Nicola Fattorelli; Nicola Thrupp; Evgenia Salta; Jesus Zoco; David Blum; Luc Buée
Journal:  EMBO Mol Med       Date:  2020-01-17       Impact factor: 12.137

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.